BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medica…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Yesterday | ||
This week | ||
Older | ||
NNebenwerte Magazin | ||
Ffinanzwelt | ||
NNebenwerte Magazin | ||
 Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
 3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||